New research by Chin-An Wang and Douglas Munoz, at Queen’s University, shows that a brain region called the intermediate superior colliculus (SCi) helps regulate the size of the pupil to optimize visual sensitivity and sharpness. Interestingly, brain processing of an object begins even before one shifts their gaze towards the object. This research shows that the size of the pupil is adjusted to the light level of the target, independent of the general light level, before the movement of the eyes towards this target. Continue reading
Read about a multidisciplinary collaboration between neuroscientists and artists, developed through The Convergence Initiative. Founded in 2016 by neuroscientist and graphic designer Dr. Cristian Zaelzer, the Convergence – Perceptions of Neuroscience initiative is a partnership with the Brain Repair and Integrative Neuroscience Program (BRaIN) of the Research Institute of the McGill University Health Centre (RI-MUHC), the Faculty of Fine Arts of Concordia University (FoFA), and the Canadian Association for Neuroscience (CAN/ACN). This partnership has been continuously supported by the RI-MUHC, the Montreal General Hospital Foundation, McGill University Integrative Program in Neurosciences (IPN), and the Visual Voice Gallery.
Dr. Keith Murai, BRaIN program director, thinks the science vs. humanities dichotomy is a false one. Continue reading
Discovery of a pathway linking Alzheimer’s disease and Type 2 Diabetes leads to new strategies to preserve brain health.
Fernanda De Felice at Queen’s University has discovered a disease mechanism common to Alzheimer’s disease and Type 2 Diabetes. This mechanism, which consist of a pathway leading to inflammation in different parts of the brain, leads to glucose intolerance, memory impairments and degeneration of the connections between neurons, called synapses. This discovery can lead the way to new therapies to preserve brain health. These results were presented at the 2018 Canadian Neuroscience Meeting, in Vancouver, May 16th, 2018. Continue reading
Researchers at UBC show that two types of cells, astrocytes and pericytes, cooperate to regenerate cerebral blood vessels to restore blood flow in brain regions damaged by stroke.
Stroke is one of three leading causes of death in Canada and leads to permanent disability in about half of survivors. During an ischemic stroke, there is a blockage of blood flow which results in cell death in a specific area or the brain. Dr. Brian MacVicar and Dr. Louis-Philippe Bernier at the University of British Columbia has recently discovered how two types of cells, called astrocytes and pericytes, work together to regenerate blood flow in the areas affected by these strokes (called ischemic areas). These results were presented at the 2018 Canadian Neuroscience Meeting, in Vancouver, May 16th, 2018. Continue reading
Rats eating a “cafeteria-diet” show changes in the brain regions that integrate information about food and determines eating behaviour.
Research by Stephanie Borgland at the University of Calgary shows that giving rats unrestricted access to unhealthy foods for extended periods not only leads to obesity, but also to brain changes that makes food more attractive to them, even when their hunger should be satisfied. Specifically, Dr. Borgland’s research identified modifications in endocannabinoid signalling in a brain region called the orbitofrontal cortex (OFC) of these obese rats. These unpublished results were presented at the 2018 Canadian Neuroscience Meeting, in Vancouver, May 15th, 2018. Continue reading
Cellular and molecular modifications in the brain of child abuse victims could explain their increased vulnerability to stress-related psychiatric disorders, including depression and suicide
Psychiatrists have long known that child abuse increases a person’s lifetime risk of psychiatric illness, including depression and suicide. New research by Naguib Mechawar and Gustavo Turecki from the McGill Group for Suicide Studies offers some explanation of the process through which abuse lastingly modifies brain wiring. Their research, which compare the brains of depressed suicides with or without a history of severe child abuse, and of healthy controls, identified important modifications in the Anterior Cingulate Cortex (ACC), a brain region critical for the regulation of moods and emotions. These findings were presented at the 2018 Canadian Neuroscience Meeting, in Vancouver, May 14th, 2018. Continue reading
The meeting will gather neuroscientists from Canada and around the world to share their research on the brain and nervous system. All areas of neuroscience research will be presented
Multiple Sclerosis is known as a progressive disease in which symptoms worsen over time. But for some 85% of those who suffer, the first stages of the illness come in waves. The individual may feel perfectly well some days while others are marked with worsening or new symptoms.
Officially this condition is known as relapsing remitting multiple sclerosis (MS) and it is the focus of a large Canadian conglomerate known as the CIHR Team in Epidemiology and Impact of Comorbidity on Multiple Sclerosis, or ECoMS. As the name implies, the group aims to determine how co-existing chronic diseases – comorbidities – affect those suffering with MS. Last week, representatives of the team, headed by Dr. Ruth Ann Marrie at the University of Manitoba and Director of Manitoba’s MS Clinic at Health Sciences Centre Winnipeg, revealed their findings in the journal, Neurology. Continue reading
Nerve injuries and neurodegenerative diseases such as Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, Multiple Sclerosis (MS) and glaucoma share some characteristics, one of which is the degeneration of a part of neurons called the axon. Axons are long extensions that branch out of the cell body to allow neurons to connect to other cells, including other neurons, to transmit signals. A team led by SickKids scientist David Kaplan with Freda Miller and their trainees Konstantin Feinberg and Adelaida Kolaj has recently identified a drug, called fortetinib, that protects axons from degeneration in multiple conditions. It may turn out to be a clinically useful therapeutic drug. Continue reading